Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

Telling yourself you're doing the best with what you have is one of many examples of compassionate self-care, writes ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...

MS is an autoimmune disorder in which the immune system attacks myelin, the protective covering of nerve fibres in the brain ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Please provide your email address to receive an email when new articles are posted on . Top-line results of a phase 2 clinical trial for an adipose-derived autologous mesenchymal stem cell therapy to ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis. NICE has said Biogen's Tysabri can now be used by the NHS ...